Mark Mcpartland News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SOUTH SAN FRANCISCO, Calif., April 25, 2024--Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo a

VistaGen Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.22, expectations were $-0.31.

Positive top-line results from Phase 3 PALISADE-2 trial of rapid-onset fasedienol (PH94B) nasal spray in social anxiety disorder (SAD)Itruvone (PH10) nasal spray now staged for Phase 2B clinical development as a stand-alone, non-systemic treatment for major depressive disorder (MDD)Positive exploratory Phase 2A tria...

Preclinical study of radiolabeled intranasal itruvone in laboratory rats further validates itruvone's potential to treat major depressive disorder without systemic absorption ...

Oral levodopa is the gold standard treatment for motor symptoms in individuals diagnosed with Parkinson’s disease, despite the risk of dyskinesia (sudden uncontrolled movements) related to long-term use of levodopaPublished preclinical data in widely used MPTP non-human primate model of Parkinson's disease show AV-1...